BPC 157 was studied almost exclusively by the same Croatian team that created it, doing rat study after rat study, while MK-677 was the domain of the Merck Research Laboratories in New Jersey, whose scientists conducted multiple small trials in humans in the 1990s, trying to see if the drug had interesting effects on a variety of surrogate markers
Mechanisms studied in BPC-157 research include angiogenesis pathways, growth factor expression related to tissue repair, inflammatory response modulation, and GI tract cellular protection
The Biden administration placed restrictions on these and a handful of other peptides in 2023 moving them into a category that essentially prohibits compounding pharmacies from making the drugs
During the off-cycle, focus on diet, probiotics, and lifestyle measures
week-0 photos (i.e
Please keep the vial away from sunlight and avoid shaking it